9,111 Shares in ANI Pharmaceuticals, Inc. $ANIP Bought by XTX Topco Ltd

XTX Topco Ltd purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 9,111 shares of the specialty pharmaceutical company’s stock, valued at approximately $594,000.

Other institutional investors have also added to or reduced their stakes in the company. Advisors Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Caitong International Asset Management Co. Ltd boosted its position in ANI Pharmaceuticals by 4,636.4% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after acquiring an additional 510 shares in the last quarter. National Bank of Canada FI purchased a new position in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $79,000. Emerald Advisers LLC raised its position in shares of ANI Pharmaceuticals by 414.8% in the 2nd quarter. Emerald Advisers LLC now owns 1,256 shares of the specialty pharmaceutical company’s stock worth $82,000 after acquiring an additional 1,012 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $209,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $82.67 on Thursday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of 50.72 and a beta of 0.48. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $99.50. The company’s 50-day moving average is $88.94 and its 200 day moving average is $79.57.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The firm had revenue of $227.81 million for the quarter, compared to the consensus estimate of $211.92 million. During the same quarter in the prior year, the firm posted $1.34 earnings per share. The business’s revenue was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Chad Gassert sold 14,642 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $89.07, for a total transaction of $1,304,162.94. Following the transaction, the senior vice president owned 158,584 shares in the company, valued at $14,125,076.88. This represents a 8.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $87.27, for a total transaction of $34,908.00. Following the completion of the sale, the vice president directly owned 75,274 shares of the company’s stock, valued at approximately $6,569,161.98. This trade represents a 0.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 25,579 shares of company stock worth $2,271,691 in the last 90 days. Corporate insiders own 12.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ANIP. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Weiss Ratings reissued a “buy (b-)” rating on shares of ANI Pharmaceuticals in a research report on Monday. Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Finally, JPMorgan Chase & Co. raised their target price on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, ANI Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $99.29.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.